News

Bevacizumab Short of Mark in First Neoadjuvant Breast Cancer Trial

Publish date: December 13, 2010

 

FROM THE SAN ANTONIO BREAST CANCER SYMPOSIUM

Dr. von Minckwitz reported that he receives grant support from Sanofi-Aventis, Roche, GlaxoSmithKline, and Novartis. Several of his coinvestigators also reported relevant financial relationships with multiple pharmaceutical companies.

Pages

Recommended Reading

Low-Dose Aspirin Therapy Doesn't Compromise iFOBT Results
MDedge Internal Medicine
Meta-Analyses Indicate Asthma Boosts Lung Cancer Risk
MDedge Internal Medicine
Outcomes of Acute Kidney Injury in Cancer Patients Studied
MDedge Internal Medicine
Frail Elderly Benefit From Post-Op Temozolomide for Glioblastoma
MDedge Internal Medicine
Even One Cigarette Is Harmful, Surgeon General's Report Finds
MDedge Internal Medicine
BEACOPP Plus ABVD Called 'New Standard' for Hodgkin's Lymphoma
MDedge Internal Medicine
Zoledronic Acid Sinks as Breast Cancer Therapy in AZURE Trial
MDedge Internal Medicine
Obesity Linked to Worse Outcomes in Common Breast Cancer Subtype
MDedge Internal Medicine
Double Cord Blood Transplant Better Than Single in Acute Leukemia
MDedge Internal Medicine
Trastuzumab/Pertuzumab Doublet Eradicates Some Early Breast Cancer
MDedge Internal Medicine